Quantcast

Latest Morphinans Stories

2014-06-06 23:01:17

A nasal-spray version of Naloxone, a heroin/opiate overdose-reversal drug, is in the works in Kentucky. (PRWEB) June 06, 2014 As reported by USA Today in the article Nasal Spray For Heroin Antidote Under Development(5/31), a Kentucky doctor has been successful in advocating a nasal spray medicine to reverse a heroin or opiate overdose. Dr. Daniel Wermeling has made a deal with a pharmaceutical company to create a nasal spray version of naloxone, a common medicine used on persons who are...

2014-06-06 16:24:14

First and Only FDA-Approved Buccal Film Formulation of Buprenorphine and Naloxone to Compete in the $1.7 Billion and Growing U.S. Opioid Dependence Market RALEIGH, N.C., June 6, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) received approval of the New Drug Application (NDA) for BUNAVAIL(TM) (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA). BUNAVAIL is indicated for the maintenance treatment of...

2014-06-05 13:33:09

University of Michigan Health System With naloxegol, adults found relief from opioid-induced constipation Pain medicines often lead to constipation for patients seeking long-term pain relief, but an investigational once-daily drug may help, according to study led by the University of Michigan Health System. Globally, approximately 28 million to 35 million, or nearly half, of patients taking opioids for long-term pain develop constipation. Laxatives provide sub-optimal relief. The...

2014-06-05 12:29:48

CHICAGO, June 5, 2014 /PRNewswire/ -- The Centers for Medicare & Medicaid Services (CMS) issued on March 14, 2014 revised guidance, "Requirements for Hospital Medication Administration, Particularly Intravenous (IV) Medications and Post-Operative Care of Patients Receiving IV Opioids". http://photos.prnewswire.com/prnvar/20131024/CG03341LOGO In an open letter to CMS discussing the guidance, the Physician-Patient Alliance for Health & Safety applauds CMS for this guidance as...

2014-06-05 08:27:57

JAMA Psychiatry Study confirms Waismann Method research that heroin addiction is prevalent in the inner-city as well as in white suburbs and rural areas. BEVERLY HILLS, Calif., June 5, 2014 /PRNewswire/ -- A research paper published in the May 28, 2014 issue of JAMA Psychiatry a paper entitled "The Changing Face of Heroin Use in the United States A Retrospective Analysis of the Past 50 Years" concluded that heroin abuse has left low-income urban areas and has become prevalent in...

2014-06-03 08:32:29

Multi-Tranche Financing Provides Sufficient Funding to Take KP201 Through and Beyond Potential FDA Approval and Enables KemPharm to Advance its Full Pipeline of Abuse-Deterrent Prodrugs CORALVILLE, Iowa, June 3, 2014 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has entered into a $60 million financing agreement with an investment fund managed by...

2014-05-30 23:05:46

The Substance Abuse Help Group Organization Comments on Efforts of Study Miami, FL (PRWEB) May 30, 2014 As reported by CBS News in the article The New Face of Heroin: Today's Users Different Than Decades Ago(5/28), a recent study has found that the demographic statistic of modern-day heroin users differs from users of the 1960's. According to the study, the most significant difference was found in gender and location. While both young men and women living in suburban and rural...

2014-05-28 08:32:01

Controlled Substance Analgesic Combination Product Uses Depomed's Proprietary Acuform® Technology NEWARK, Calif., May 28, 2014 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-155. MNK-155 is an investigational extended-release oral formulation of hydrocodone and acetaminophen that has been studied for the management of moderate to...

2014-05-27 08:29:52

ALISO VIEJO, Calif., May 27, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced completion of patient enrollment in the company's phase II, placebo controlled study testing AVP-923 for the treatment of agitation in Alzheimer's disease patients. Top-line results from this study are expected late September/early October. http://photos.prnewswire.com/prnvar/20130207/LA55901LOGO "Final completion of enrollment in this study is an important milestone for...

2014-05-21 23:10:53

Healthesystems clinicians assembled a valuable resource for workers’ compensation payers to share with prescribers who are treating patients for chronic pain with opioid therapy. Tampa, Fla. (PRWEB) May 21, 2014 Implementation of an aggressive opioid management strategy that includes opioid dose tapering can minimize risks to injured workers and workers’ compensation claims organizations. Long-term opioid therapy carries significant risks and can lead to complex, escalating and...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.